ArticlePloS one2017
Adenovirus-vectored novel African Swine Fever Virus antigens elicit robust immune responses in swine.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 86 citations in OpenAlex.
- Dual Antiviral Functions of Antibodies Targeting African Swine Fever Virus p17 Protein: Viral Inhibition and ADCC Induction.Viruses · 2026Article
- Egg Yolk Antibodies Elicited by a Novel Multi-Epitope Recombinant Adenovirus Vaccine Against Genotype G2b PEDV Spike Protein Reduce Mortality and Viral Shedding in Passively Immunized Piglets.Pathogens (Basel, Switzerland) · 2026Article
- Advances in African swine fever vaccine development: challenges and prospects.Journal of veterinary science · 2026Review
- African swine fever virus genes vectored by simian adenoviruses do not protect against virulent genotype II virus challenge.Microbiology spectrum · 2026Article
- African Swine Fever: Vaccine Advancement and Major Gaps.Microorganisms · 2026Review
- Immunogenicity assessment and epitope mapping of the ASFV proteome by profiling serum antibodies with ASFV antigen phage libraries.Communications biology · 2026Article
- Live-vectored antigen cocktail confers protection against African swine fever virus (ASFV) Georgia 2007/1 challenge.NPJ vaccines · 2026Article
- Article
- Antibody-Dependent Cellular Cytotoxicity Elicited by the Antibodies Against the E120R Protein of African Swine Fever Virus.Vaccines · 2025Article
- Article
- Progress in African Swine Fever Vector Vaccine Development.International journal of molecular sciences · 2025Review
- Molecular Mechanism of VSV-Vectored ASFV Vaccine Activating Immune Response in DCs.Veterinary sciences · 2025Article
- Safety and Immunogenicity of Recombinant Adeno-Associated Virus-Vectored African Swine Fever Virus Antigens.Veterinary medicine international · 2025Article
- Construction and Evaluation of Quadruple-Gene-Deleted Pseudorabies Virus Platforms for ASFV Antigen Delivery.Transboundary and emerging diseases · 2025Article
- Newcastle Disease Virus-Vectored African Swine Fever Virus Antigen Cocktail Delays the Onset of ASFV-SY18 but Is Not Protective.Microorganisms · 2024Article
- Identification of cepharanthine as an effective inhibitor of African swine fever virus replication.Emerging microbes & infections · 2024Article
- Review
- Navigating the threat of African swine fever: a comprehensive review.Tropical animal health and production · 2024Review
- Preparation and epitope analysis of monoclonal antibodies against African swine fever virus DP96R protein.BMC veterinary research · 2024Article
- Recent progress and major gaps in the vaccine development for African swine fever.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
African Swine Fever Virus (ASFV) is a high-consequence transboundary animal pathogen that often causes hemorrhagic disease in swine with a case fatality rate close to 100%. Lack of treatment or vaccine for the disease makes it imperative that safe and efficacious vaccines are developed to safeguard the swine industry. In this study, we evaluated the immunogenicity of seven adenovirus-vectored novel ASFV antigens, namely A151R, B119L, B602L, EP402RΔPRR, B438L, K205R and A104R. Immunization of commercial swine with a cocktail of the recombinant adenoviruses formulated in adjuvant primed strong ASFV antigen-specific IgG responses that underwent rapid recall upon boost. Notably, most vaccinees mounted robust IgG responses against all the antigens in the cocktail. Most importantly and relevant to vaccine development, the induced antibodies recognized viral proteins from Georgia 2007/1 ASFV-infected cells by IFA and by western blot analysis. The recombinant adenovirus cocktail also induced ASFV-specific IFN-γ-secreting cells that were recalled upon boosting. Evaluation of local and systemic effects of the recombinant adenovirus cocktail post-priming and post-boosting in the immunized animals showed that the immunogen was well tolerated and no serious negative effects were observed. Taken together, these outcomes showed that the adenovirus-vectored novel ASFV antigen cocktail was capable of safely inducing strong antibody and IFN-γ+ cell responses in commercial swine. The data will be used for selection of antigens for inclusion in a multi-antigen prototype vaccine to be evaluated for protective efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.